Prospective multicenter study of HX575 (biosimilar epoetin-α) in patients with chronic kidney disease applying a target hemoglobin of 10 - 12 g/dl

Clinical Nephrology

Volumn 78, Issue 1, 2012, Pages 24-32

  Hörl, Walter H ^a   Locatelli, Francesco ^b   Haag Weber, Marianne ^c   Ode, Marité ^d,e   Roth, Karsten ^d,e  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b A MANZONI HOSPITAL   (Italy)

^c Urologische Klinik   (Germany)

^d Sandoz Pharma Ltd   (Switzerland)

^e Epo PASS study group ^*  (Germany)

Author keywords

Anemia; Biosimilar; CKD; Clinical study; Epoetin

Indexed keywords

CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; EPOBIOCRIN; EPOVITAN; GEMAX; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; UNCLASSIFIED DRUG; WEPOX; ANTIANEMIC AGENT; BIOLOGICAL MARKER; BIOSIMILAR AGENT; ERYTHROPOIETIN; RECOMBINANT PROTEIN;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ADULT; AGED; ANEMIA; ANGINA PECTORIS; ARTERIOVENOUS FISTULA; ARTICLE; BLADDER CANCER; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; DRUG EFFICACY; FEMALE; HEART ARREST; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEMOGLOBIN BLOOD LEVEL; HUMAN; ISCHEMIC CARDIOMYOPATHY; MAJOR CLINICAL STUDY; MALE; MELANOMA; MULTICENTER STUDY; OPEN STUDY; PROSPECTIVE STUDY; SHUNT THROMBOSIS; SIDE EFFECT; SUDDEN DEATH; TRANSIENT ISCHEMIC ATTACK; VEIN THROMBOSIS; BLOOD; CHEMICALLY INDUCED DISORDER; CHRONIC DISEASE; CLINICAL TRIAL; EUROPE; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY DISEASE; METABOLISM; MIDDLE AGED; NEOPLASM; THROMBOSIS; TIME; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANEMIA; BIOLOGICAL MARKERS; BIOSIMILAR PHARMACEUTICALS; CHRONIC DISEASE; ERYTHROPOIETIN; EUROPE; FEMALE; HEMATINICS; HEMOGLOBINS; HUMANS; INJECTIONS, INTRAVENOUS; KIDNEY DISEASES; MALE; MIDDLE AGED; NEOPLASMS; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; THROMBOSIS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84864558128     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CN107440     Document Type: Article

References (12)

1. Sörgel F, Thyroff-Friesinger U, Vetter A, Vens-Cappell B, Kinzig M. Bioequivalence of HX575 (recombinant human epoetin alfa) and a comparator epoetin alfa after multiple intravenous administrations: an open-label randomised controlled trial. BMC Clin Pharmacol. 2009; 9: 10 doi:10.1186/1472-6904-9-10 PubMed.
2. Sörgel F, Thyroff-Friesinger U, Vetter A, Vens-Cappell B, Kinzig M. Biosimilarity of HX575 (human recombinant epoetin alfa) and epoetin beta after multiple subcutaneous administration. Int J Clin Pharmacol Ther. 2009; 47: 391-401. PubMed.
3. Sörgel F, Thyroff-Friesinger U, Vetter A, Vens-Cappell B, Kinzig M. Bioequivalence of HX575 (recombinant human epoetin alfa) and a comparator epoetin alfa after multiple subcutaneous administrations. Pharmacology. 2009; 83: 122-130. doi:10.1159/000189027 PubMed.
4. Haag-Weber M, Vetter A, Thyroff-Friesinger U; INJ-Study Group. Therapeutic equivalence, longterm efficacy and safety of HX575 in the treatment of anemia in chronic renal failure patients receiving hemodialysis. Clin Nephrol. 2009; 72: 380-390. PubMed.
5. Weigang-Köhler K, Vetter A, Thyroff-Friesinger U. HX575, recombinant human epoetin alfa, for the treatment of chemotherapy-associated symptomatic anaemia in patients with solid tumours. Onkologie. 2009; 32: 168-174. doi:10.1159/000200783 PubMed.
6. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D; CHOIR Investigators. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006; 355: 2085-2098. doi:10.1056/NEJMoa065485 PubMed.
7. Drüeke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, Burger HU, Scherhag A; CREATE Investigators. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006; 355: 2071-2084. doi:10.1056/NEJMoa062276 PubMed.
8. Stevens LA, Li S, Wang C, Huang C, Becker BN, Bomback AS, Brown WW, Burrows NR, Jurkovitz CT, McFarlane SI, Norris KC, Shlipak M, Whaley-Connell AT, Chen SC, Bakris GL, McCullough PA. Prevalence of CKD and comorbid illness in elderly patients in the United States: results from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis. 2010; 55 (Suppl 2): S23-S33. doi:10.1053/j.ajkd.2009.09.035 PubMed.
9. Locatelli F, Pisoni RL, Combe C, Bommer J, Andreucci VE, Piera L, Greenwood R, Feldman HI, Port FK, Held PJ. Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant. 2004; 19: 121-132. doi:10.1093/ndt/gfg458 PubMed.
10. Verdalles U, Abad S, Aragoncillo I, Villaverde M, Jofre R, Verde E, Vega A, López-Gómez JM. Factors predicting mortality in elderly patients on dialysis. Nephron Clin Pract. 2010; 115: c28-c34. doi:10.1159/000286347 PubMed.
11. Shirazian S, Radhakrishnan J. Gastrointestinal disorders and renal failure: exploring the connection. Nat Rev Nephrol. 2010; 6: 480-492. doi:10.1038/nrneph.2010.84 PubMed.
12. Couchoud C, Moranne O, Frimat L, Labeeuw M, Allot V, Stengel B. Associations between comorbidities, treatment choice and outcome in the elderly with end-stage renal disease. Nephrol Dial Transplant. 2007; 22: 3246-3254. doi:10.1093/ndt/gfm400 PubMed.